Mylan beats Street's estimates with Q3 earnings and beats Perrigo in effort to derail tender

Mylan ($MYL) has swept aside one of the legal hurdles set up by Perrigo ($PRGO), which has been fighting on two continents to try to derail Mylan's takeover of the generics competitor. Mylan said today that a U.S. federal court ruled it has provided adequate explanations about the cost savings from combining the two companies, denying Perrigo's request for a temporary injunction. Perrigo also has an action pending in a court in Israel, where Perrigo's shares are listed. The win came as Mylan posted Q3 earnings of $1.43 per share, exceeding analyst projections of $1.38 per share. Earnings release | Court ruling release | More

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.